124 related articles for article (PubMed ID: 22489801)
1. Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells.
Zhao Y; Sun X; Jiang L; Yang F; Zhang Z; Jia L
Cancer Invest; 2012 May; 30(4):287-94. PubMed ID: 22489801
[TBL] [Abstract][Full Text] [Related]
2. AXL mediates resistance to cetuximab therapy.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
[TBL] [Abstract][Full Text] [Related]
3. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
4. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
[TBL] [Abstract][Full Text] [Related]
5. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
6. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.
Ma Y; Zhou G; Li M; Hu D; Zhang L; Liu P; Lin K
Neurochem Int; 2018 Sep; 118():233-241. PubMed ID: 29572052
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
9. Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.
Li Y; Jia L; Liu C; Gong Y; Ren D; Wang N; Zhang X; Zhao Y
Tumour Biol; 2015 Feb; 36(2):1115-27. PubMed ID: 25327287
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion.
Yen SY; Chen SR; Hsieh J; Li YS; Chuang SE; Chuang HM; Huang MH; Lin SZ; Harn HJ; Chiou TW
Oncogene; 2016 Apr; 35(17):2156-65. PubMed ID: 26257061
[TBL] [Abstract][Full Text] [Related]
12. Axl inhibitors as novel cancer therapeutic agents.
Shen Y; Chen X; He J; Liao D; Zu X
Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
[TBL] [Abstract][Full Text] [Related]
13. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
14. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
16. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
Liu R; Gong M; Li X; Zhou Y; Gao W; Tulpule A; Chaudhary PM; Jung J; Gill PS
Blood; 2010 Jul; 116(2):297-305. PubMed ID: 20442363
[TBL] [Abstract][Full Text] [Related]
17. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
[TBL] [Abstract][Full Text] [Related]
18. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
19. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
[TBL] [Abstract][Full Text] [Related]
20. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
